NDATOPICALSOLUTIONPriority Review
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
Priority Review
ROGAINE (FOR MEN) (minoxidil) by Design Pharmaceuticals is clinical pharmacology 1. First approved in 1988.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rogaine (minoxidil) is a topical solution containing minoxidil, a peripheral vasodilator originally developed for oral hypertension treatment. It is applied directly to the scalp to stimulate hair growth in men experiencing androgenetic alopecia. The mechanism involves enhanced microcirculatory blood flow to hair follicles, prolonging the anagen (growth) phase and increasing hair density.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential reduction in brand investment and team restructuring opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. General Pharmacologic Properties Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Microcirculatory blood flow in animals is enhanced or maintained…
Worked on ROGAINE (FOR MEN) at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.